Find information on thousands of medical conditions and prescription drugs.

Carbachol

|} Carbachol (Kar-ba-kol ), also known as carbamylcholine (sold under the brand names Carbastat&reg:, Carboptic&reg:, Isopto Carbachol&reg:, Miostat), is classified as a cholinergic. It is primarily used in the treatment of glaucoma, but is also used during ophthalmic surgery. In most countries it is only available by prescription. Carbachol eyedrops are used to decrease the pressure in the eye for people with glaucoma. It is sometimes used to constrict the pupils during cataract surgery. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

In the cat and rat, carbachol is well-known for its ability to induce rapid eye movement (REM) sleep when microinjected into the pontine reticular formation. Carbachol elicits this REM sleep-like state via activation of postsynaptic muscarinic cholinergic receptors (mAChRs).

Clinical Info

Chemistry and pharmacokinetics

Carbachol is a choline ester and a positively charged quaternary ammonium compound. It is not well absorbed in the gastro-intestinal tract and does not cross the blood-brain barrier. It is usually administered topical ocular or through intraocular injection. Carbachol is not easily metabolized by cholinesterase, its duration of action is 4 to 8 hours with topical administration and 24 hours for intraocular administration. Since carbachol is poorly absorbed through topical administration, benzalkonium chloride is mixed in to promote absorption.

Mechanisms of action

Carbachol is a parasympathomimetic that stimulates both muscarinic and nicotinic receptors. In topical ocular and intraocular administration its principal effects are miosis and increased aqueous humour outflow.

Indications

Topical occular administration is used to decrease intraocular pressure in people with primary open-angle glaucoma. Intraocular administration is used to produce miosis after lens implantation during cataract surgery. Carbachol can also be used to stimulate bladder emptying if the normal emptying mechanism is not working properly.

Contraindications and precautions

Use of carbachol, as well as all other muscarinic receptor agonists, is contraindicated in patients with asthma, coronary insufficiency, gastroduodenal ulcers, and incontinence. The parasympathomimetic action of this drug will exacerbate the symptoms of these disorders.

Overdose

Sources

  • Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
  • Canadian Pharmacists Association (2000). Compendium of pharmaceuticals and specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
  • Carbachol (1998). MedlinePlus. Retrieved June 27, 2004, from
  • Carbachol (2003). RxList. Retrieved June 27, 2004, from
  • National Institute for Occupational Safety and Health. (2002). Choline, chloride, carbamate. In The registry of toxic effects of chemical substances. Retrieved June 27, 2004, from
  • Carbachol Chloride (2004). Hazardous Substances Data Bank. Retrieved July 16, 2004, from

Read more at Wikipedia.org


[List your site here Free!]


Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists
From Journal of Drugs in Dermatology, 5/1/04

The authors in this study injected littermates of neonatal athymic nude mice with pemphigus vulgaris (PV) to determine whether a cholinergic agonist can abolish PV IgG-induced acantholysis. Previous studies have determined the importance of cholinergic receptors in the pathogenesis of PV. The authors measured the expression of adhesion molecules in monolayers of normal human keratinocytes via in-vitro methods with the addition of carbachol. None of the mice in the current study developed skin lesions.

Carbachol is a cholinergic (parasympathomimetic) agent. Carbachol has the double action of a) stimulating the motor endplate of the muscle cell, and b) partially inhibiting cholinesterase.

The results of the study were that the phosphorylation levels of E-cadherin and plakoglobin were increased by PV IgG, and carbachol decreased PV IgG. Pyridostigmine bromide, an acetylcholinesterase (AChE) inhibitor, produced effects similar to those of carbachol, which helps explain its clinical efficacy in a patient with active PV that was resistant to treatment with systemic glucocorticosteroids. The authors then treated a steroid-recalcitrant PV patient with pyridostigmine bromide (360 mg/d) in a patient with PV. The patient was kept at a lower dose of prednisone than that used before starting pyridostigmine bromide treatment and the disease was well controlled. The authors conclude that cholinergic agents not only can treat, but can reverse the acantholysis effects of PV IgG.

JDD ARTICLE EVALUATION:

Pemphigus vulgaris (PV) is an autoimmune, IgG autoantibody-mediated disease targeting desmoglein-3 of the skin and mucosa, leading to progressive blistering and erosions. Recent studies have detected autoantibodies to keratinocyte cholinergic receptors regulating cell adhesion (1).

Acetylcholine and its nicotinic and muscarinic receptors are located in the epidermis and adnexal structures. These receptors are also found on melanocytes, fibroblasts, endothelial cells, and immune cells. Furthermore, the cholinergic system is involved in the functions of the keratinocytes such as differentiation; it is also involved in epidermal barrier formation, sweating, angiogenesis, and immune reactions.

As patients affected with PV have altered cholinergic pathways, cholinergic agonists may present new therapeutic methods in treating PV. The method of action of cholinergic agonists is not completely understood, but theories involve inhibition of AChE receptors to the phosphorylation of cell membrane-associated proteins. It seems that cholinergic agonists block alterations caused by PV IgG antibodies to the cell membrane.

All in all, cholinergic agonists block cell damage caused by PV IgG and increase desmogleins 1 and 3. The mechanism is not fully understood, but the possibility of treating other blistering disorders has been raised. The risks of this medication are the cholinergic side effects of diarrhea and muscle weakness, a point the authors failed to detail. Overall this was a good study that needs a more controlled and randomized evaluation.

References

1. Kurzen H. The extraneuronal cholinergic system of the skin: basic facts and clinical relevance. Hautarzt 2004 Apr: [E-pub ahead of print].

Nguyen VT, et al. Arch Dermatol 2004; 140(3):327-34.

COPYRIGHT 2004 Journal of Drugs in Dermatology
COPYRIGHT 2004 Gale Group

Return to Carbachol
Home Contact Resources Exchange Links ebay